The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia

被引:11
作者
Espinosa, Gerard [1 ]
Prieto-Gonzalez, Sergio [2 ]
Llevadot, Mireia [3 ]
Marco-Hernandez, Javier [2 ]
Martinez-Artuna, Antonio [3 ]
Perez-Isidro, Albert [4 ]
Rife, Elia [3 ]
Cervera, Ricard [1 ]
机构
[1] Univ Barcelona, Hosp Clin, Dept Autoimmune Dis, Barcelona 08036, Spain
[2] Univ Barcelona, Hosp Clin, Dept Internal Med, Barcelona, Spain
[3] Univ Barcelona, Fac Med & Hlth Sci, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin, Dept Immunol, Barcelona, Spain
关键词
COVID-19; Hydroxychloroquine; Outbreak; SARS-CoV-2; infection; Systemic lupus erythematosus; COVID-19; INDEX;
D O I
10.1007/s10067-021-05675-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population. Methods For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated. Results Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) Conclusions The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered.
引用
收藏
页码:2057 / 2063
页数:7
相关论文
共 50 条
  • [41] Urticaria and coronavirus infection: a lesson from SARS-CoV-2 pandemic
    Allegra, A.
    Asero, R.
    Giovannetti, A.
    Isola, S.
    Gangemi, S.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 53 (02) : 51 - 54
  • [42] Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
    Saxena, Amit
    Guttmann, Allison
    Masson, Mala
    Kim, Mimi Y.
    Haberman, Rebecca H.
    Castillo, Rochelle
    Scher, Jose U.
    Deonaraine, Kristina K.
    Engel, Alexis J.
    Belmont, H. Michael
    Blazer, Ashira D.
    Buyon, Jill P.
    Fernandez-Ruiz, Ruth
    Izmirly, Peter M.
    LANCET RHEUMATOLOGY, 2021, 3 (08) : E585 - E594
  • [43] The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study
    Gerosa, Maria
    Schioppo, Tommaso
    Argolini, Lorenza Maria
    Sciascia, Savino
    Ramirez, Giuseppe Alvise
    Moroni, Gabriella
    Sinico, Renato Alberto
    Bonelli, Grazia
    Alberici, Federico
    Mescia, Federica
    Moroni, Luca
    Tamborini, Francesco
    Miraglia, Paolo
    Bellocchi, Chiara
    Beretta, Lorenzo
    Roccatello, Dario
    Dagna, Lorenzo
    Bozzolo, Enrica
    Caporali, Roberto
    VACCINES, 2022, 10 (05)
  • [44] A systematic review on impact of SARS-CoV-2 infection
    Thirumugam, Gowripriya
    Radhakrishnan, Yashwanth
    Ramamurthi, Suresh
    Bhaskar, James Prabhanand
    Krishnaswamy, Balamurugan
    MICROBIOLOGICAL RESEARCH, 2023, 271
  • [45] Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
    Mormile, Ilaria
    Della Casa, Francesca
    Petraroli, Angelica
    Furno, Alessandro
    Granata, Francescopaolo
    Portella, Giuseppe
    Rossi, Francesca Wanda
    de Paulis, Amato
    VACCINES, 2022, 10 (08)
  • [46] Psychosocial impact of SARS- CoV-2 outbreak on patients with pediatric-onset systemic lupus erythematosus and their caregivers
    Sharma, Rajni
    Chaudhary, Himanshi
    Patra, Pratap
    Sudhakar, Murugan
    Anjani, Gummadi
    Jindal, Ankur
    Pandiarajan, Vignesh
    Gupta, Anju
    Suri, Deepti
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (12) : 7920 - 7925
  • [47] A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2
    Zavala-Flores, Ernesto
    Salcedo-Matienzo, Jannin
    Huamanchumo-Guzman, Roberto
    Berrocal-Kasay, Alfredo
    Alarcon, Graciela S.
    LUPUS, 2024, 33 (03) : 282 - 288
  • [48] Serositis and lymphopenia are common features of systemic lupus erythematosus following SARS-CoV-2 infection: A case report and literature review
    Kioi, Yoshiyuki
    Yorifuji, Hideki
    Higami, Yuichi
    Katada, Yoshinori
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (11) : 2267 - 2271
  • [49] Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
    Konig, Maximilian F.
    Kim, Alfred H. J.
    Scheetz, Marc H.
    Graef, Elizabeth R.
    Liew, Jean W.
    Simard, Julia
    Machado, Pedro M.
    Gianfrancesco, Milena
    Yazdany, Jinoos
    Langguth, Daman
    Robinson, Philip C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1386 - 1388
  • [50] Recovery of systemic hyperinflammation in patients with severe SARS-CoV-2 infection
    Langnau, Carolin
    Janing, Henrik
    Kocaman, Hueseyin
    Gekeler, Sarah
    Guenter, Manina
    Petersen-Uribe, Alvaro
    Jaeger, Philippa
    Koch, Barbara
    Kreisselmeier, Klaus-Peter
    Castor, Tatsiana
    Rath, Dominik
    Gawaz, Meinrad Paul
    Autenrieth, Stella E.
    Mueller, Karin Anne Lydia
    BIOMARKERS, 2023, 28 (01) : 97 - 110